During the past decade, Szpital Uniwersytecki w Krakowie conducted 60 clinical trials. In the 10-year time frame, 60 clinical trials started and 29 clinical trials were completed, i.e. on average, 48.3% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 14 clinical trials were completed. i.e. 51.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szpital Uniwersytecki w Krakowie" #1 sponsor was "Janssen Research & Development, LLC" with 7 trials, followed by "Jagiellonian University" with 6 trials sponsored, "Gilead Sciences" with 5 trials sponsored, "Pfizer" with 5 trials sponsored and "Takeda" with 5 trials sponsored. Other sponsors include 61 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Uniwersytecki w Krakowie" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Novartis" with 2 trials as a collaborator, "Population Health Research Institute" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Azienda Ospedaliera dei Colli" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Uniwersytecki w Krakowie" are "Coronary Artery Disease" (6 trials), "Multiple Myeloma" (5 trials), "Fabry Disease" (3 trials), "Polycythemia Vera" (3 trials) and "Primary Myelofibrosis" (3 trials). Many other conditions were trialed in "Szpital Uniwersytecki w Krakowie" in a lesser frequency.

Most popular intervention types in "Szpital Uniwersytecki w Krakowie" are "Drug" (68 trials), "Device" (11 trials), "Biological" (8 trials), "Other" (8 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Dexamethasone" (7 trials), "placebo" (6 trials), "Daratumumab" (4 trials) and "Bortezomib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Uniwersytecki w Krakowie" are 89 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 37 active trials in "Szpital Uniwersytecki w Krakowie". 1 are not yet recruiting, 21 are recruiting, 14 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 44 completed trials in Szpital Uniwersytecki w Krakowie, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Uniwersytecki w Krakowie, 3 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 7 trials that are defined as “Not Applicable".

Szpital Uniwersytecki w Krakowie has several departments that took part in Clinical trials: "Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii" - 23 trials, "SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej" - 8 trials, "Oddzial Kliniczny Kliniki Hematologii" - 5 trials, "Oddzial Kardiologii" - 2 trials, "Clinic of Endocrinology Independent Public Health Care Centre University Hospital in Kracow" - 2 trials, "Univ. Hospital in Krakow,Pulmonology Clinical Dept" - 2 trials